empty
 
 

01.07.202413:06:00UTC+00Neurocrine's NDA For Crinecerfont To Treat Congenital Adrenal Hyperplasia Gets Priority Review

Neurocrine Biosciences, Inc. (NBIX) announced on Monday that the U.S. Food and Drug Administration (FDA) has granted priority reviews for the company's New Drug Applications (NDAs) for crinecerfont. This medication is aimed at treating children, adolescents, and adults with congenital adrenal hyperplasia (CAH).

Congenital adrenal hyperplasia is a set of genetic disorders impacting the adrenal glands, which hinders normal growth and development in children.

The NDAs cover both a capsule and an oral solution formulation of crinecerfont. The FDA's decision dates are set for December 29 and December 30, 2024, respectively.

If approved, crinecerfont will be the first new treatment option for CAH in 70 years.

  • Grand Choice
    Contest by
    InstaForex
    InstaForex always strives to help you
    fulfill your biggest dreams.
    JOIN CONTEST
  • Chancy Deposit
    Deposit your account with $3,000 and get $4000 more!
    In July we raffle $4000 within the Chancy Deposit campaign!
    Get a chance to win by depositing $3,000 to a trading account. Having fulfilled this condition, you become a campaign participant.
    JOIN CONTEST
  • Trade Wise, Win Device
    Top up your account with at least $500, sign up for the contest, and get a chance to win mobile devices.
    JOIN CONTEST
  • 30% Bonus
    Receive a 30% bonus every time you top up your account
    GET BONUS


Can't speak right now?
Ask your question in the chat.
Widget callback